PS1: Tailored development of biosimilars without efficacy and safety studies – Is this the future?
By Janine Jamieson2025-11-18T09:58:00
Key points:
- Regulatory thinking regarding biosimilars has evolved since the first biosimilars were approved in the EU in 2006
- Improved analytical technologies and understanding of modes of action and structure-function relationships, coupled with an excellent safety record, now enable the waiver of clinical efficacy studies
To read more key points and the session summary, login as a member or register for free using the links below.